Calliditas Therapeutics AB (publ)
Get $10 bonus on your first $100 deposit for CALT
Get $10 bonus on your first $100 deposit for CALT
Calliditas Therapeutics AB (publ) (CALT) Stock Competitors & Peer Comparison
See (CALT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CALT | $40.00 | -0.10% | 2.1B | -22.73 | -$1.76 | N/A |
| VRTX | $438.63 | -1.27% | 112.2B | 28.85 | $15.31 | N/A |
| REGN | $750.02 | -0.73% | 78.3B | 18.17 | $41.49 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $831.53 | +0.38% | 52.1B | 42.92 | $19.60 | N/A |
| ALNY | $326.77 | -3.73% | 44.2B | 141.82 | $2.35 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $142.35 | -7.20% | 31.6B | -22.86 | -$6.42 | N/A |
| RVMD | $154.21 | +4.90% | 30.2B | -25.64 | -$5.95 | N/A |
| UTHR | $577.36 | -0.20% | 25.3B | 20.75 | $27.84 | N/A |
Stock Comparison
CALT vs VRTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, VRTX has a market cap of 112.2B. Regarding current trading prices, CALT is priced at $40.00, while VRTX trades at $438.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas VRTX's P/E ratio is 28.85. In terms of profitability, CALT's ROE is -0.85%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CALT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check VRTX's competition here
CALT vs REGN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, REGN has a market cap of 78.3B. Regarding current trading prices, CALT is priced at $40.00, while REGN trades at $750.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas REGN's P/E ratio is 18.17. In terms of profitability, CALT's ROE is -0.85%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CALT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check REGN's competition here
CALT vs VRNA Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CALT is priced at $40.00, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CALT's ROE is -0.85%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, CALT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check VRNA's competition here
CALT vs ARGX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ARGX has a market cap of 52.1B. Regarding current trading prices, CALT is priced at $40.00, while ARGX trades at $831.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ARGX's P/E ratio is 42.92. In terms of profitability, CALT's ROE is -0.85%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, CALT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ARGX's competition here
CALT vs ALNY Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ALNY has a market cap of 44.2B. Regarding current trading prices, CALT is priced at $40.00, while ALNY trades at $326.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ALNY's P/E ratio is 141.82. In terms of profitability, CALT's ROE is -0.85%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, CALT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ALNY's competition here
CALT vs SGEN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CALT is priced at $40.00, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CALT's ROE is -0.85%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CALT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check SGEN's competition here
CALT vs INSM Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, INSM has a market cap of 31.6B. Regarding current trading prices, CALT is priced at $40.00, while INSM trades at $142.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas INSM's P/E ratio is -22.86. In terms of profitability, CALT's ROE is -0.85%, compared to INSM's ROE of -1.68%. Regarding short-term risk, CALT is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check INSM's competition here
CALT vs RVMD Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, RVMD has a market cap of 30.2B. Regarding current trading prices, CALT is priced at $40.00, while RVMD trades at $154.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas RVMD's P/E ratio is -25.64. In terms of profitability, CALT's ROE is -0.85%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, CALT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check RVMD's competition here
CALT vs UTHR Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, UTHR has a market cap of 25.3B. Regarding current trading prices, CALT is priced at $40.00, while UTHR trades at $577.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas UTHR's P/E ratio is 20.75. In terms of profitability, CALT's ROE is -0.85%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CALT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check UTHR's competition here
CALT vs BNTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, BNTX has a market cap of 25B. Regarding current trading prices, CALT is priced at $40.00, while BNTX trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas BNTX's P/E ratio is -18.15. In terms of profitability, CALT's ROE is -0.85%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, CALT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check BNTX's competition here
CALT vs MRNA Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, CALT is priced at $40.00, while MRNA trades at $53.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas MRNA's P/E ratio is -7.47. In terms of profitability, CALT's ROE is -0.85%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CALT is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check MRNA's competition here
CALT vs ROIV Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ROIV has a market cap of 21B. Regarding current trading prices, CALT is priced at $40.00, while ROIV trades at $29.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ROIV's P/E ratio is -25.12. In terms of profitability, CALT's ROE is -0.85%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, CALT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ROIV's competition here
CALT vs RPRX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, RPRX has a market cap of 20.9B. Regarding current trading prices, CALT is priced at $40.00, while RPRX trades at $48.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas RPRX's P/E ratio is 27.36. In terms of profitability, CALT's ROE is -0.85%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CALT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check RPRX's competition here
CALT vs BGNE Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CALT is priced at $40.00, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CALT's ROE is -0.85%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, CALT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check BGNE's competition here
CALT vs INCY Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, CALT is priced at $40.00, while INCY trades at $95.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas INCY's P/E ratio is 15.15. In terms of profitability, CALT's ROE is -0.85%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CALT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check INCY's competition here
CALT vs DNA-WT Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CALT is priced at $40.00, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CALT's ROE is -0.85%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, CALT is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check DNA-WT's competition here
CALT vs GMAB Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, GMAB has a market cap of 18.1B. Regarding current trading prices, CALT is priced at $40.00, while GMAB trades at $28.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas GMAB's P/E ratio is 19.03. In terms of profitability, CALT's ROE is -0.85%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, CALT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check GMAB's competition here
CALT vs SMMT Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, SMMT has a market cap of 15.7B. Regarding current trading prices, CALT is priced at $40.00, while SMMT trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas SMMT's P/E ratio is -14.67. In terms of profitability, CALT's ROE is -0.85%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, CALT is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CALT.Check SMMT's competition here
CALT vs BBIO Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, BBIO has a market cap of 15.1B. Regarding current trading prices, CALT is priced at $40.00, while BBIO trades at $76.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas BBIO's P/E ratio is -20.56. In terms of profitability, CALT's ROE is -0.85%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, CALT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check BBIO's competition here
CALT vs ASND Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, CALT is priced at $40.00, while ASND trades at $239.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ASND's P/E ratio is -54.93. In terms of profitability, CALT's ROE is -0.85%, compared to ASND's ROE of +1.28%. Regarding short-term risk, CALT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ASND's competition here
CALT vs IONS Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, IONS has a market cap of 12.7B. Regarding current trading prices, CALT is priced at $40.00, while IONS trades at $75.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas IONS's P/E ratio is -32.28. In terms of profitability, CALT's ROE is -0.85%, compared to IONS's ROE of -0.69%. Regarding short-term risk, CALT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check IONS's competition here
CALT vs KRTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CALT is priced at $40.00, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CALT's ROE is -0.85%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CALT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check KRTX's competition here
CALT vs JAZZ Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, JAZZ has a market cap of 12.3B. Regarding current trading prices, CALT is priced at $40.00, while JAZZ trades at $198.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas JAZZ's P/E ratio is -34.13. In terms of profitability, CALT's ROE is -0.85%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, CALT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check JAZZ's competition here
CALT vs MDGL Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, CALT is priced at $40.00, while MDGL trades at $517.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas MDGL's P/E ratio is -40.36. In terms of profitability, CALT's ROE is -0.85%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, CALT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check MDGL's competition here
CALT vs EXEL Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, CALT is priced at $40.00, while EXEL trades at $44.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas EXEL's P/E ratio is 15.93. In terms of profitability, CALT's ROE is -0.85%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, CALT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check EXEL's competition here
CALT vs RNAM Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CALT is priced at $40.00, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CALT's ROE is -0.85%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CALT is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check RNAM's competition here
CALT vs BMRN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, CALT is priced at $40.00, while BMRN trades at $55.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas BMRN's P/E ratio is 30.71. In terms of profitability, CALT's ROE is -0.85%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, CALT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check BMRN's competition here
CALT vs ARWR Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ARWR has a market cap of 9.9B. Regarding current trading prices, CALT is priced at $40.00, while ARWR trades at $69.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ARWR's P/E ratio is 44.34. In terms of profitability, CALT's ROE is -0.85%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, CALT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ARWR's competition here
CALT vs RXDX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CALT is priced at $40.00, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CALT's ROE is -0.85%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CALT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check RXDX's competition here
CALT vs AXSM Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, AXSM has a market cap of 9.4B. Regarding current trading prices, CALT is priced at $40.00, while AXSM trades at $182.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas AXSM's P/E ratio is -49.91. In terms of profitability, CALT's ROE is -0.85%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, CALT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check AXSM's competition here
CALT vs TECH Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, CALT is priced at $40.00, while TECH trades at $57.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas TECH's P/E ratio is 110.36. In terms of profitability, CALT's ROE is -0.85%, compared to TECH's ROE of +0.04%. Regarding short-term risk, CALT is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check TECH's competition here
CALT vs IMGN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CALT is priced at $40.00, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CALT's ROE is -0.85%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CALT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check IMGN's competition here
CALT vs PCVX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, PCVX has a market cap of 8.7B. Regarding current trading prices, CALT is priced at $40.00, while PCVX trades at $60.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas PCVX's P/E ratio is -10.74. In terms of profitability, CALT's ROE is -0.85%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, CALT is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check PCVX's competition here
CALT vs BPMC Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CALT is priced at $40.00, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CALT's ROE is -0.85%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, CALT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check BPMC's competition here
CALT vs CERE Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CALT is priced at $40.00, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CERE's P/E ratio is -16.47. In terms of profitability, CALT's ROE is -0.85%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CALT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CERE's competition here
CALT vs HALO Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, CALT is priced at $40.00, while HALO trades at $68.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas HALO's P/E ratio is 26.58. In terms of profitability, CALT's ROE is -0.85%, compared to HALO's ROE of +0.93%. Regarding short-term risk, CALT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check HALO's competition here
CALT vs CYTK Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CYTK has a market cap of 8.1B. Regarding current trading prices, CALT is priced at $40.00, while CYTK trades at $64.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CYTK's P/E ratio is -10.00. In terms of profitability, CALT's ROE is -0.85%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, CALT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CYTK's competition here
CALT vs IBRX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, IBRX has a market cap of 8B. Regarding current trading prices, CALT is priced at $40.00, while IBRX trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas IBRX's P/E ratio is -20.47. In terms of profitability, CALT's ROE is -0.85%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, CALT is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check IBRX's competition here
CALT vs ABVX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, CALT is priced at $40.00, while ABVX trades at $119.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ABVX's P/E ratio is -21.55. In terms of profitability, CALT's ROE is -0.85%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, CALT is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ABVX's competition here
CALT vs KRYS Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, KRYS has a market cap of 7.9B. Regarding current trading prices, CALT is priced at $40.00, while KRYS trades at $265.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas KRYS's P/E ratio is 39.26. In terms of profitability, CALT's ROE is -0.85%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CALT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check KRYS's competition here
CALT vs NUVL Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, CALT is priced at $40.00, while NUVL trades at $102.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas NUVL's P/E ratio is -17.91. In terms of profitability, CALT's ROE is -0.85%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, CALT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check NUVL's competition here
CALT vs MTSR Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CALT is priced at $40.00, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CALT's ROE is -0.85%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CALT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check MTSR's competition here
CALT vs KYMR Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, KYMR has a market cap of 7.3B. Regarding current trading prices, CALT is priced at $40.00, while KYMR trades at $87.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas KYMR's P/E ratio is -24.12. In terms of profitability, CALT's ROE is -0.85%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, CALT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check KYMR's competition here
CALT vs PRAX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, PRAX has a market cap of 7.2B. Regarding current trading prices, CALT is priced at $40.00, while PRAX trades at $330.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas PRAX's P/E ratio is -25.22. In terms of profitability, CALT's ROE is -0.85%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, CALT is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check PRAX's competition here
CALT vs MRUS Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CALT is priced at $40.00, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CALT's ROE is -0.85%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CALT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check MRUS's competition here
CALT vs BLTE Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, CALT is priced at $40.00, while BLTE trades at $160.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas BLTE's P/E ratio is -73.06. In terms of profitability, CALT's ROE is -0.85%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, CALT is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check BLTE's competition here
CALT vs PTGX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, CALT is priced at $40.00, while PTGX trades at $103.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas PTGX's P/E ratio is -51.43. In terms of profitability, CALT's ROE is -0.85%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, CALT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check PTGX's competition here
CALT vs ACLX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CALT is priced at $40.00, while ACLX trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ACLX's P/E ratio is -28.25. In terms of profitability, CALT's ROE is -0.85%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CALT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ACLX's competition here
CALT vs RETA Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CALT is priced at $40.00, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas RETA's P/E ratio is -66.29. In terms of profitability, CALT's ROE is -0.85%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CALT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check RETA's competition here
CALT vs PTCT Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, CALT is priced at $40.00, while PTCT trades at $72.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas PTCT's P/E ratio is 8.57. In terms of profitability, CALT's ROE is -0.85%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, CALT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check PTCT's competition here
CALT vs RYTM Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, CALT is priced at $40.00, while RYTM trades at $88.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas RYTM's P/E ratio is -28.23. In terms of profitability, CALT's ROE is -0.85%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, CALT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check RYTM's competition here
CALT vs CELC Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, CALT is priced at $40.00, while CELC trades at $123.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CELC's P/E ratio is -32.49. In terms of profitability, CALT's ROE is -0.85%, compared to CELC's ROE of -2.03%. Regarding short-term risk, CALT is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CELC's competition here
CALT vs CAI Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CAI has a market cap of 5.9B. Regarding current trading prices, CALT is priced at $40.00, while CAI trades at $20.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CAI's P/E ratio is -6.51. In terms of profitability, CALT's ROE is -0.85%, compared to CAI's ROE of +0.25%. Regarding short-term risk, CALT is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CAI's competition here
CALT vs CNTA Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, CALT is priced at $40.00, while CNTA trades at $39.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CNTA's P/E ratio is -27.13. In terms of profitability, CALT's ROE is -0.85%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, CALT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CNTA's competition here
CALT vs COGT Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, CALT is priced at $40.00, while COGT trades at $35.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas COGT's P/E ratio is -16.81. In terms of profitability, CALT's ROE is -0.85%, compared to COGT's ROE of -1.00%. Regarding short-term risk, CALT is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check COGT's competition here
CALT vs CGON Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, CALT is priced at $40.00, while CGON trades at $66.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CGON's P/E ratio is -32.54. In terms of profitability, CALT's ROE is -0.85%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CALT is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CGON's competition here
CALT vs SRRK Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, CALT is priced at $40.00, while SRRK trades at $49.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas SRRK's P/E ratio is -14.99. In terms of profitability, CALT's ROE is -0.85%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, CALT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check SRRK's competition here
CALT vs ERAS Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, CALT is priced at $40.00, while ERAS trades at $17.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ERAS's P/E ratio is -41.36. In terms of profitability, CALT's ROE is -0.85%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, CALT is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ERAS's competition here
CALT vs CDTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CALT is priced at $40.00, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CALT's ROE is -0.85%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CALT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CDTX's competition here
CALT vs IMVT Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, CALT is priced at $40.00, while IMVT trades at $27.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas IMVT's P/E ratio is -10.27. In terms of profitability, CALT's ROE is -0.85%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, CALT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check IMVT's competition here
CALT vs ALKS Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ALKS has a market cap of 5.5B. Regarding current trading prices, CALT is priced at $40.00, while ALKS trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ALKS's P/E ratio is 23.22. In terms of profitability, CALT's ROE is -0.85%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, CALT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ALKS's competition here
CALT vs TGTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, TGTX has a market cap of 5.5B. Regarding current trading prices, CALT is priced at $40.00, while TGTX trades at $34.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas TGTX's P/E ratio is 12.49. In terms of profitability, CALT's ROE is -0.85%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, CALT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check TGTX's competition here
CALT vs ABCM Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CALT is priced at $40.00, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CALT's ROE is -0.85%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CALT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ABCM's competition here
CALT vs ISEE Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CALT is priced at $40.00, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CALT's ROE is -0.85%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CALT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ISEE's competition here
CALT vs CRSP Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, CALT is priced at $40.00, while CRSP trades at $55.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CRSP's P/E ratio is -8.77. In terms of profitability, CALT's ROE is -0.85%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, CALT is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CRSP's competition here
CALT vs FBIOX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, CALT is priced at $40.00, while FBIOX trades at $25.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CALT's ROE is -0.85%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, CALT is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check FBIOX's competition here
CALT vs APLS Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, CALT is priced at $40.00, while APLS trades at $40.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas APLS's P/E ratio is 226.92. In terms of profitability, CALT's ROE is -0.85%, compared to APLS's ROE of +0.08%. Regarding short-term risk, CALT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check APLS's competition here
CALT vs APGE Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, APGE has a market cap of 5B. Regarding current trading prices, CALT is priced at $40.00, while APGE trades at $88.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas APGE's P/E ratio is -21.17. In terms of profitability, CALT's ROE is -0.85%, compared to APGE's ROE of -0.37%. Regarding short-term risk, CALT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check APGE's competition here
CALT vs MIRM Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, CALT is priced at $40.00, while MIRM trades at $95.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas MIRM's P/E ratio is -205.11. In terms of profitability, CALT's ROE is -0.85%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, CALT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check MIRM's competition here
CALT vs TERN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, CALT is priced at $40.00, while TERN trades at $52.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas TERN's P/E ratio is -51.17. In terms of profitability, CALT's ROE is -0.85%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CALT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check TERN's competition here
CALT vs CORT Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CORT has a market cap of 4.7B. Regarding current trading prices, CALT is priced at $40.00, while CORT trades at $43.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CORT's P/E ratio is 53.54. In terms of profitability, CALT's ROE is -0.85%, compared to CORT's ROE of +0.15%. Regarding short-term risk, CALT is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CORT's competition here
CALT vs XENE Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, CALT is priced at $40.00, while XENE trades at $58.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas XENE's P/E ratio is -13.50. In terms of profitability, CALT's ROE is -0.85%, compared to XENE's ROE of -0.56%. Regarding short-term risk, CALT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check XENE's competition here
CALT vs FOLD Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CALT is priced at $40.00, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas FOLD's P/E ratio is -160.67. In terms of profitability, CALT's ROE is -0.85%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CALT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check FOLD's competition here
CALT vs AKRO Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CALT is priced at $40.00, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CALT's ROE is -0.85%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CALT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check AKRO's competition here
CALT vs LGND Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, LGND has a market cap of 4.5B. Regarding current trading prices, CALT is priced at $40.00, while LGND trades at $223.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas LGND's P/E ratio is 36.72. In terms of profitability, CALT's ROE is -0.85%, compared to LGND's ROE of +0.14%. Regarding short-term risk, CALT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check LGND's competition here
CALT vs ALPN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CALT is priced at $40.00, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CALT's ROE is -0.85%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CALT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ALPN's competition here
CALT vs OPT Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CALT is priced at $40.00, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas OPT's P/E ratio is -1.52. In terms of profitability, CALT's ROE is -0.85%, compared to OPT's ROE of +0.88%. Regarding short-term risk, CALT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check OPT's competition here
CALT vs SYRE Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, SYRE has a market cap of 4.2B. Regarding current trading prices, CALT is priced at $40.00, while SYRE trades at $69.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas SYRE's P/E ratio is -34.84. In terms of profitability, CALT's ROE is -0.85%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, CALT is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check SYRE's competition here
CALT vs CRNX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, CALT is priced at $40.00, while CRNX trades at $39.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CRNX's P/E ratio is -8.03. In terms of profitability, CALT's ROE is -0.85%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, CALT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CRNX's competition here
CALT vs MRTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CALT is priced at $40.00, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CALT's ROE is -0.85%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CALT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check MRTX's competition here
CALT vs VKTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, CALT is priced at $40.00, while VKTX trades at $35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas VKTX's P/E ratio is -11.11. In terms of profitability, CALT's ROE is -0.85%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, CALT is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check VKTX's competition here
CALT vs NAMS Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, CALT is priced at $40.00, while NAMS trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas NAMS's P/E ratio is -19.77. In terms of profitability, CALT's ROE is -0.85%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, CALT is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check NAMS's competition here
CALT vs LEGN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, CALT is priced at $40.00, while LEGN trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas LEGN's P/E ratio is -12.67. In terms of profitability, CALT's ROE is -0.85%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, CALT is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for CALT.Check LEGN's competition here
CALT vs TVTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, TVTX has a market cap of 3.8B. Regarding current trading prices, CALT is priced at $40.00, while TVTX trades at $39.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas TVTX's P/E ratio is -71.84. In terms of profitability, CALT's ROE is -0.85%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, CALT is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check TVTX's competition here
CALT vs RYZB Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CALT is priced at $40.00, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CALT's ROE is -0.85%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CALT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check RYZB's competition here
CALT vs CBAY Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CALT is priced at $40.00, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CALT's ROE is -0.85%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CALT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CBAY's competition here
CALT vs ACAD Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, CALT is priced at $40.00, while ACAD trades at $21.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas ACAD's P/E ratio is 9.46. In terms of profitability, CALT's ROE is -0.85%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, CALT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check ACAD's competition here
CALT vs DNTH Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, CALT is priced at $40.00, while DNTH trades at $92.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas DNTH's P/E ratio is -22.80. In terms of profitability, CALT's ROE is -0.85%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, CALT is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check DNTH's competition here
CALT vs EWTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, CALT is priced at $40.00, while EWTX trades at $33.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas EWTX's P/E ratio is -20.67. In terms of profitability, CALT's ROE is -0.85%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, CALT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check EWTX's competition here
CALT vs TLX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, CALT is priced at $40.00, while TLX trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas TLX's P/E ratio is -533.00. In terms of profitability, CALT's ROE is -0.85%, compared to TLX's ROE of -0.02%. Regarding short-term risk, CALT is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check TLX's competition here
CALT vs SWTX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CALT is priced at $40.00, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CALT's ROE is -0.85%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, CALT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check SWTX's competition here
CALT vs LQDA Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, LQDA has a market cap of 3.5B. Regarding current trading prices, CALT is priced at $40.00, while LQDA trades at $40.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas LQDA's P/E ratio is -50.15. In terms of profitability, CALT's ROE is -0.85%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, CALT is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check LQDA's competition here
CALT vs DNLI Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, DNLI has a market cap of 3.4B. Regarding current trading prices, CALT is priced at $40.00, while DNLI trades at $21.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas DNLI's P/E ratio is -7.30. In terms of profitability, CALT's ROE is -0.85%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, CALT is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check DNLI's competition here
CALT vs KNSA Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, CALT is priced at $40.00, while KNSA trades at $45.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas KNSA's P/E ratio is 61.19. In terms of profitability, CALT's ROE is -0.85%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, CALT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check KNSA's competition here
CALT vs DYN Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, DYN has a market cap of 3.3B. Regarding current trading prices, CALT is priced at $40.00, while DYN trades at $19.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas DYN's P/E ratio is -5.76. In terms of profitability, CALT's ROE is -0.85%, compared to DYN's ROE of -0.61%. Regarding short-term risk, CALT is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check DYN's competition here
CALT vs CPRX Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, CALT is priced at $40.00, while CPRX trades at $25.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas CPRX's P/E ratio is 15.39. In terms of profitability, CALT's ROE is -0.85%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CALT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check CPRX's competition here
CALT vs BEAM Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, BEAM has a market cap of 3.1B. Regarding current trading prices, CALT is priced at $40.00, while BEAM trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas BEAM's P/E ratio is -37.88. In terms of profitability, CALT's ROE is -0.85%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, CALT is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check BEAM's competition here
CALT vs GPCR Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, CALT is priced at $40.00, while GPCR trades at $53.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas GPCR's P/E ratio is -22.60. In terms of profitability, CALT's ROE is -0.85%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, CALT is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check GPCR's competition here
CALT vs VERA Comparison April 2026
CALT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CALT stands at 2.1B. In comparison, VERA has a market cap of 3.1B. Regarding current trading prices, CALT is priced at $40.00, while VERA trades at $42.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CALT currently has a P/E ratio of -22.73, whereas VERA's P/E ratio is -9.32. In terms of profitability, CALT's ROE is -0.85%, compared to VERA's ROE of -0.60%. Regarding short-term risk, CALT is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for CALT.Check VERA's competition here